Intellia Therapeutics Files Q2 2024 10-Q
Ticker: NTLA · Form: 10-Q · Filed: Aug 8, 2024 · CIK: 1652130
Sentiment: neutral
Topics: 10-Q, biotech, financials
Related Tickers: NTLA
TL;DR
**Intellia Therapeutics (NTLA) filed its Q2 2024 10-Q, detailing financials and operations.**
AI Summary
Intellia Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and business operations. Key financial data points and operational updates are detailed within the filing, which covers the second quarter of 2024.
Why It Matters
This filing provides investors and stakeholders with a detailed look at Intellia's financial health and operational progress during the second quarter of 2024, crucial for understanding the company's trajectory in the gene editing space.
Risk Assessment
Risk Level: medium — As a biotechnology company, Intellia Therapeutics operates in a high-risk, high-reward sector with significant research and development expenses and regulatory hurdles.
Key Numbers
- 2024-06-30 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
- 2024-08-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Filer of the 10-Q
- 2024-06-30 (date) — End of the reporting period
- 2024-08-08 (date) — Filing date of the 10-Q
- 001-37766 (other) — SEC File Number
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed with the SEC on August 8, 2024.
What is the company's Central Index Key (CIK)?
Intellia Therapeutics, Inc.'s Central Index Key (CIK) is 0001652130.
What is the company's SEC file number?
The SEC file number for Intellia Therapeutics, Inc. is 001-37766.
What is the company's fiscal year end?
Intellia Therapeutics, Inc.'s fiscal year ends on December 31.
Filing Stats: 4,315 words · 17 min read · ~14 pages · Grade level 16.9 · Accepted 2024-08-08 16:06:13
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Ma
Filing Documents
- ntla-20240630.htm (10-Q) — 2232KB
- ntla-ex10_1.htm (EX-10.1) — 46KB
- ntla-ex10_4.htm (EX-10.4) — 124KB
- ntla-ex31_1.htm (EX-31.1) — 13KB
- ntla-ex31_2.htm (EX-31.2) — 13KB
- ntla-ex32_1.htm (EX-32.1) — 8KB
- 0000950170-24-093907.txt ( ) — 8327KB
- ntla-20240630.xsd (EX-101.SCH) — 1170KB
- ntla-20240630_htm.xml (XML) — 1321KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
Financial Statements (unaudited)
Item 1. Financial Statements (unaudited) Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 4 Condensed Consolidated Statements of Stockholders' Equity for the Six Months Ended June 30, 2024 and 2023 5 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 6 Notes to Condensed Consolidated Financial Statements 7
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 19
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 29
Controls and Procedures
Item 4. Controls and Procedures . 30
- OTHER INFORMATION
PART II - OTHER INFORMATION
Legal Proceedings
Item 1. Legal Proceedings 31
Risk Factors
Item 1A. Risk Factors 31 I tem 2. Unregistered Sales of Equity Securities and Use of Proceeds 74
Other Information
Item 5. Other Information 75
Exhibits
Item 6. Exhibits 76
– FINANCI AL INFORMATION
PART I – FINANCI AL INFORMATION
Financi al Statements
Item 1. Financi al Statements INTELLIA THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (unaudited) (Amounts in thousands except share and per share data) June 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 130,849 $ 226,748 Marketable securities 560,219 685,475 Accounts receivable 12,329 36,456 Prepaid expenses and other current assets 53,814 49,651 Total current assets 757,211 998,330 Marketable securities - noncurrent 248,805 99,864 Property and equipment, net 30,273 32,760 Operating lease right-of-use assets 105,412 115,375 Equity method investment - 11,765 Investments and other assets 49,835 42,883 Total assets $ 1,191,536 $ 1,300,977 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 18,816 $ 7,452 Accrued expenses 45,127 67,017 Current portion of operating lease liability 18,963 18,599 Current portion of deferred revenue 22,184 22,140 Total current liabilities 105,090 115,208 Deferred revenue, net of current portion 28,052 38,853 Long-term operating lease liability 87,332 96,747 Total liabilities 220,474 250,808 Commitments and contingencies (Note 6) Stockholders' equity: Common stock, $ 0.0001 par value; 240,000,000 shares authorized at June 30, 2024 and December 31, 2023; 98,289,150 and 92,997,158 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 10 9 Additional paid-in capital 2,884,997 2,710,797 Accumulated other comprehensive loss ( 1,155 ) ( 2,258 ) Accumulated deficit ( 1,912,790 ) ( 1,658,379 ) Total stockholders' equity 971,062 1,050,169 Total liabilities and stockholders' equity $ 1,191,536 $ 1,300,977 See notes to condensed consolidated financial statements. 3 INTELLIA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive